A multimarker approach that includes inflammatory markers can aid in risk stratification
Numerous studies have demonstrated the utility of a multimarker approach to stratifying cardiovascular disease.1,2,3 When combined with standard lipid testing, inflammatory marker testing allows for additional risk stratification, and may be considered for patients with4:
- Low-to-moderate risk, identified as >5% of the estimated CVD risk
- Established cardiovascular disease
- Diabetes
- Hypertension
- Metabolic syndrome, as defined by having any 3 of 5 conditions: central obesity, elevated triglycerides, low HDL-C, elevated blood pressure, or elevated plasma glucose
- Dyslipidemia
Go beyond traditional risk factors. Learn more about inflammatory marker testing:
Uncovering hidden risk: the importance of inflammatory markers
Monitoring a patient’s inflammatory status may help you to uncover hidden risk from early to advanced stages of cardiovascular disease. With deeper insights, you can take further action to help reduce your patients’ cardiovascular risk.
This information is provided for informational purposes only and is not intended as medical advice. A physician’s test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.
References
1. Penn MS, Klemes AB. Multimarker approach for identifying and documenting mitigation of cardiovascular risk. Future Cardiol. 2013;9(4):497-506. doi:10.2217/fca.13.27
2. Ikonomidis I, Mihalakeas CA, Lekakis J, et al. Multimarker approach in cardiovascular risk prediction. Dis Markers. 2009;26(5-6):273-285. doi:10.3233/DMA-2009-0633
3. Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129-2138. doi:10.1016/j.jacc.2009.09.009
4. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
During the COVID-19 health crisis, fast action and trusted information matter more than ever.
Find out what's happening
Cardiovascular disease
Cardiovascular
Save time & fix billing issues
Avoid disruptions and reduce paperwork with electronic billing trailers.
Raise patient satisfaction and get the insights you need
Access better patient tools, view test offerings, improve your bottom line, and more.
- Site map
- Privacy Notices
- Terms
- Contact us
- Language assistance / non-discrimination
- Asistencia de idiomas / Aviso de no discriminación
- 語言協助 / 不歧視通知
- Accessibility
- Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.